skip to Main Content

Emodin Alleviates Gemcitabine Resistance in Pancreatic Cancer by Inhibiting MDR1/P‑Glycoprotein and MRPs Expression

Emodin Alleviates Gemcitabine Resistance in Pancreatic Cancer by Inhibiting MDR1/P‑Glycoprotein and MRPs Expression
Gemcitabine is a gold standard chemotherapeutic agent for pancreatic cancer. However, gemcitabine has limited effectiveness due to the short‑term development of chemoresistance. Emodin, a natural anthraquinone derivative isolated from the roots of rheumatic palm leaves prevents immunosuppression and exerts anticancer effects.

The present study aimed to evaluate the effect of emodin on gemcitabine resistance. Gemcitabine‑resistant PANC‑1 pancreatic cancer cell xenografts were established in athymic mice, which were randomly assigned into four treatments groups as follows: Gemcitabine group, Emodin group, Gemcitabine+Emodin group and Negative control group. Body weight, tumor volume and tumor weight were measured over the course of treatment. The effect of each treatment on tumor tissue proliferation and apoptosis from nude mice was evaluated by using immunohistochemistry. Read more . . .


Back To Top